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Background: Diagnosis of tuberculous pleurisy is difficult and better diagnostic tools are
needed. Interferon gamma release assays (IGRAs) are in vitro immunologic diagnostic tests
used to identify Mycobacterium TB infections. They cannot differentiate between latent
and active infections. As IGRA tests have recently been approved for the differential diag-
nosis of active TB, the diagnostic accuracy of the latest generation of IGRAwere assessed to
detect tuberculous pleurisy in this study.
Methods: The QuantiFERONTB-Gold (QFT-G) test was used in pleural fluid from 100 immu-
nocompetent patients (23 patients for the tuberculous group and 77 patients for the
non-tuberculous group). Clinical data were recorded. Adenosine deaminase activity
(ADA) analysis and TB culture were performed on pleural fluid.
Results: The QFT-G in pleural fluid was positive in 10 (43.5%) patients and indeterminate in
13(56.5%) patients in the tuberculous pleurisy group. There was not a single patient with a
negative test result in the tuberculous pleurisy group. The ADA levels were detected as
46.2 ± 12.6 in patients with tuberculous pleurisy and18.6 ± 39.8 in patients with non-
tuberculous pleurisy. The sensitivity, specificity, positive predictive value and negative
predictive value of QFT-G in pleural fluid for tuberculous pleurisy were 43.5%, 54.5%,
30.3% and 100%; and of ADA in pleural fluid (>40 IU/ml) for tuberculous pleurisy the results
were 82.6%, 96.1%, 90.5% and 92.5% respectively.
Conclusion: While the value of the QFT-G test in exclusion of tuberculous pleurisy was
found to be higher in this study, its other diagnostic efficiency values were detected to be
low. It is recommended that a new cut-off value be established while diagnosing active
TB in prospective clinical studies and that it is also essential to do the same for the studies
in various regions with high and low prevalence of TB.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Tuberculous pleurisy is the most common cause of exudative
pleural effusion and it is also one of the most common forms
of extrapulmonary tuberculosis (TB) in Turkey [1]. Definitive-African Society for Myco
(B. Komurcuoglu).TB diagnosis is based on the detection of Mycobacterium
tuberculosis (MTB) in the culture of pleural fluid or pleural
biopsy specimens, which usually takes 4–6 weeks. Supportive
evidence includes the demonstration of classical tuberculous
granulomas in the pleura, elevated adenosine deaminasebacteriology. All rights reserved.
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fluids [2]. As a result of the increase in T-lymphocytes in pleu-
ral fluid, the diagnosis of tuberculous pleurisy in the studies
that focus on the usages of lymphokines released from lym-
phocytes have shown an increase in recent years. The most
emphasized of these lymphokines is the IFN-c released from
activated CD4+ T-lymphocytes [3,4]. In 2010, the Centers for
Disease Control and Prevention (CDC) updated its guidelines
for testing TB infection concluding that ‘‘IGRAs [Interferon
gamma release assays] may be used instead of a tuberculin
skin test in all situations in which the CDC suggests the tuber-
culin skin test as an aid in diagnosing MTB infection [5].’’ This
prospective study was aimed at determining the role of the
QFT-G-IT test in the diagnosis of tuberculous pleurisy.
Materials and methods
Patients presenting with pleural effusion admitted to the Dr.
SuatSeren Education and Research Hospital for Chest Dis-
eases and Thoracic Surgery, _Izmir, Turkey, in the period Janu-
ary 2009–October 2009 were recruited into the study. The
patients were categorized as ‘Tuberculous’ pleurisy (study
group, Acid-Fast Bacillus [AFB] microscopy or culture-positive
pleural fluid or tissue and/or specific histology for TB), and
‘non-tuberculous’ pleurisy when diagnosed as malignancy
or another non-tuberculous condition (control group). Thora-
cocentesis and pleural biopsies were obtained according to
clinical practice at the hospital. Ethical approval and signed
informed consent for the study was obtained.
QuantiFERONTB-Gold assay: 1 ml pleural fluid, provided by
the manufacturer (Cellestis Ltd., Victoria, Australia) was
added to each of the tuberculous antigens, positive mitogen
control (phytohemagglutinin [PHA]) and Nil control and
mixed well and incubated at 37 C for 20 h. The tubes were
centrifuged and 500 ll of the supernatants was harvested
and stored at 70 C until the IFN-cwas measured in an ELISA
reader. The IFN-c concentrations (IU/ml) were calculated by
the ‘QFT-G-IT analysis Software.’ The test was positive if the
tuberculous antigen minus Nil value was P0.35 IU/ml. The
Nil control was 68 IU/ml and PHA (positive control) minus
Nil was P0.5 IU/ml or tuberculous antigen minus Nil value
was P0.35 IU/ml and P25% of the Nil for the subject to have
a valid QFT-G test.
The pleural fluid was also sent for analysis of ADA using a
commercial colorimetric assay kit (Diazyme General Atomics,
California) with a cutoff value for a positive test of 40 U/L.
Statistics
The statistical analysis was performed by SPSS 14 (SPSS Inc.,
Chicago, Illinois, USA). IFN-c and ADA responses were shown
as median and ranges. The results were analysed through ex-
act Mann–Whitney U and Kruskal–Wallis tests (including post
hoc Mann–Whitney tests with Bonferroni correction for a
group of three post hoc comparisons) for a comparison be-
tween the tuberculous and non-tuberculous groups. Also,
IFN-c responses within the tuberculous group were analysed
through exact paired sample Wilcoxon tests. The Spearman
correlation coefficient was computed regarding the associa-tions between continuous variables. A p-value of <0.05 was
considered to signify a statistically significant difference.
The sensitivity, specificity, positive predictive value and nega-
tive predictive value of QFT-G and ADA tests for tuberculous
pleurisy were calculated.
Results
A total of 100 patients (23 patients for the tuberculous group
and 77 patients for the non-tuberculous group) were enrolled
in the study. The patients’ characteristics were presented in
Table 1. The median age was 57.3 ± 17.1 (18–99) and male to
female ratio was 80/20. The end diagnosis of patients in the
non-tuberculous group were malignant pleurisy, non-specific
pleurisy, paraneumonic pleurisy, paraneoplastic pleurisy,
conjunctive heart and kidney failure related to transudate
and empyema in 30 (30%), 17 (17%), 14 (14%), 10 (10%), 7 (7%)
and 3 (3%) of patients, respectively.
The QFT-G test results and mean ADA levels for the ‘tuber-
culous’ and ‘non-tuberculous’ cases are as given in Table 2.
The QFT-G test was positive in 10 (43.5%) patients and indeter-
minate in 13 (56.5%) patients in the tuberculous pleurisy
group. There was not a single patient with a negative test re-
sult in the tuberculous pleurisy group. The ADA levels were
detected as 45.0 (28–88) in patients with tuberculous pleurisy
and 13.5 (1–223) in patients with non-tuberculous pleurisy.
The diagnostic efficacy of pleural fluid QFT-G and ADA
tests in patients with tuberculous pleurisy groups were pre-
sented in Table 3. The sensitivity, specificity, positive predic-
tive value and negative predictive value of QFT-G test for
tuberculous pleurisy were 43.5%, 54.5%, 30.3% and 100%,
respectively. The sensitivity, specificity, positive predictive va-
lue and negative predictive value of ADA (>40 IU/ml) for tuber-
culous pleurisy were 82.6%, 96.1%, 90.5% and 92.5%.
The mean ADA level was less than 40 IU/ml in all patients
with non-tuberculous pleural effusion. However, the mean
ADA levels were higher than 41 IU/ml in 19 (82.6%) patients
and lower than 40 IU/ml in 4 (17.4%) patients with tuberculous
pleural effusion.
Discussion
The diagnosis of tuberculous pleurisy is generally difficult and
the acid fast bacilli (AFB) microscopy method rarely detects
the tubercle bacilli, whereas the culture is positive in about
40% of cases, but it requires 2–6 weeks to grow. Histology of
pleural biopsies could offer a sensitivity of up to 80% in
immunocompetent patients. However, this procedure re-
quires greater expertise, is more invasive, and is subject to
sampling error. Due to these limitations of conventional tests,
plus the delay of several weeks for mycobacterial culture re-
sults, newer rapid tests and biomarkers such as polymerase
chain reaction, ADA and IFN-c in pleural fluid have been eval-
uated [4,6–8].
ADA, released from active lymphocytes, macrophages and
neutrophils, is a non-specific marker of inflammation. A
meta-analysis concludes that ADA and its isoenzymes in
pleural fluid is used as a marker of tuberculous pleurisy. How-
ever, empyema, rheumatoid pleurisy and malignancy may
Table 2 – Pleural fluid QFT-TB Gold test results and ADA levels.
Type ADA levels QuantiFERONTB-Gold test
Mean (range) Negative Positive Indeterminate
Tuberculous 45.0 (28–88) 0 10 13
Non-tuberculous
Malignant 10.0 (4–25) 16 11 3
Paramalignant 11.0 (10–18) 8 2 0
Parapneumonic 11.0 (6–20) 7 4 3
Empyema 201.0 (23–223) 2 0 1
Transudate 4.50 (1–10) 4 1 2
Non-specific 9.0 (6–23) 5 5 3
Total 13.5 (1–223) 42 33 25
Table 1 – Baseline characteristics of patients.
Type n (%) Male/female Mean age ± SD (range)
Tuberculous 23 (23%) 20/3 41.3 ± 19.0 (18–82)
Non-tuberculous 77(77%) 60/17
Malignant 30(30%) 19/11 62.9 ± 13.6 (22–82)
Non-specific 13 (13%) 10/3 55.6 ± 12.8 (27–69)
Parapneumonic 14 (14%) 13/1 63.5 ± 14.7 (45–99)
Paraneoplastic 10 (10%) 10/0 63.1 ± 13.7 (29–78)
Transudate 7 (7%) 7/0 65.1 ± 11.3 (48–80)
Empyema 3 (3%) 1/2 65.3 ± 7.0 (58–72)
Total 100 (100%) 80/20 57.3 ± 17.1 (18–99)
Table 3 – Diagnostic efficacy of pleural fluid QFT-G and ADA tests in TB pleurisy.
Result QuantiFERONTB-Gold (%) ADA (>40 IU/ml) (%)
Sensitivity 43.5 82.6
Specificity 54.5 96.1
Positive predictive value 30.3 90.5
Negative predictive value 100 92.5
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sitivity, specificity, and negative predictive value of ADA (va-
lueP 45.5 IU/ml) for tuberculous pleurisy were 88.1%, 85.7%
and 88.2% respectively [7]. The sensitivity, specificity, positive
predictive value and negative predictive value of ADA (>40 IU/
ml) for tuberculous pleurisy were 82.6%, 96.1%, 90.5% and
92.5% respectively.
IFN-c usage in tuberculous pleurisy diagnosis was de-
scribed by Ribera, in 1988 [12]. Poyraz et al. compared the 15
patients with tuberculous pleural effusion and 20 patients
with malignant pleural effusion, and they reported the IFN-c
sensitivity and specificity were 87%, 95% for tuberculous pleu-
ral effusion and positive and negative predictive values were
93% and 90%, respectively [13]. Kokturk et al. showed that
when the IFN-c level of the pleural fluid in tuberculous pleu-
risy is evaluated together with pleural fluid/serum IFN-c level,
the diagnostic ratio would be 100%. There is currently no
comment with regard to the issue of IFN-c not evaluated in
the serum. The concerned study attracts attention since it is
the first one carried out in which this ratioing was evaluatedand it was proved that all tuberculous pleurisies could be
diagnosed [14]. The combinations of the tests, especially the
ones including ADA, seem to be yielding better results than
the usage of one single test (ADAP 40 U/L) [15].
IGRAs are in vitro immunologic diagnostic tests used to
identify MTB infection. Latent and active infections are not
differentiated. Several test systems are commercially avail-
able: QuantiFERONTB-Gold (QFT-G), QuantiFERONTB-Gold
in-Tube (QFT-G-IT), both Cellestis Limited, Chadstone, Austra-
lia; and T-SPOT TB (Oxford Immunotec, Abingdon, UK). The
QFT-G and QFT-G-IT is based on the measurement of IFN-c se-
creted from T-cells previously exposed to MTB when stimu-
lated in vitro with the MTB-specific antigens early secretory
antigenic target 6 (ESAT-6), culture filtrate protein 10 (CFP-
10) and Rv2654 (TB 7.7). Their use in clinical practice is becom-
ing more andmore widespread. Whereas the test was initially
conceived to support diagnosis of latent infection, an increas-
ing body of evidence has been published on its use in
detection of active TB infection [16,17]. More and more guide-
lines now include recommendations for or against the use of
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systematic reviews and meta-analyses have recently been
published, specifically on the diagnostic accuracy of IGRAs
in active TB [18–20]. Strong heterogeneity between study pop-
ulations is a major limitation of these meta-analyses, and
most studies have had small sample sizes.
Specificity depends highly on the definition of the control
group. Pai et al. reported a pooled specificity of 99% among
non-BCG vaccinated and 96% among BCG-vaccinated low-risk
groups [21]. According to a recent meta-analysis that was not
restricted to studies on specificity to low-risk groups [20], the
specificity of QFT-G was only 0.79 (95% CI 0.75–0.82).
Sensitivity in these studies was also found to be highly
dependent on the study population, notably local TB preva-
lence, and ranged from 0.58 in a high-prevalence country
[23] to 1.00 in a low-prevalence country [20] when QFT-G
was assessed. Diel et al. found a pooled sensitivity of 0.84
(95% CI 0.81–0.87) when he included only developed countries
[20], which was consistent with the results published by Sest-
er et al. (0.77, 95% CI 0.75–0.80) [19]. Vesenbeckh et al. assessed
the diagnostic accuracy of the latest generation IGRA for
detection of active TB in a low-incidence area in Germany.
Their consecutive case series included 61 HIV negative, MTB
culture-positive patients, as well as 234 control patients. In
11/61 patients with active TB (18.0%), the test result was
<0.35 IU/mL, resulting in a sensitivity of 0.82. They recom-
mended establishing a new cut-off value for the differential
diagnosis of active TB assessed by prospective clinical studies
and in various regions with high and low prevalence of TB
[22].
Baba et al. evaluated the utility of the QFT-G test as a diag-
nostic tool of tuberculous pleurisy in a high TB and HIV ende-
mic area. The QFT-G test in pleural fluid was positive in 27%
and 56% of the ‘confirmed TB’ and ‘probable TB’ cases, respec-
tively, whereas the corresponding sensitivities in blood were
58% and 83%. They concluded that the commercial QFT-G test
in blood could prove useful in the diagnosis of tuberculous
pleurisy in the HIV-positive population in order to urge initia-
tion of TB therapy. Although the QFT-G test in pleural fluid in
certain cases could contribute to the TB diagnosis in HIV pa-
tients with low CD4 cell counts, they did not support the rou-
tine use of this test in pleural fluid at this stage [23].
The QFT-G test is technically more complicated and more
expensive than established biomarkers, and its diagnostic
performance for active pleural TB is highly variable between
studies and settings [24]. As well as complying with large vol-
ume testing and showing flexibility in analysis, some studies
concerning the QFT-G test show that the high background
IFN-c level in the negative control tube precludes the usage
of pleural fluid that was not additionally processed [25]. In
antigen-based tests such as ELISA, false positive and negative
results can be obtained owing to the antigen/antibody excess
or with other proteins causing a cross-reaction. There are
some researchers who suggest diluting in order to preclude
the cases in which the test is indetermined as a result of anti-
gen/antibody excess. Hence, if a false positive result is ob-
tained because the sample contains foreign protein, since it
decreases in number after diluting, there is no non-specific
attachment and the result turns into negative. In one study,
the results of the first test performed on a TB group showed5 samples to be positive and 4 samples to be indeterminate
as they consisted of unreadably high values. After diluting
the pleural fluid in a 1:1 ratio, the indetermined results were
found to be positive (prezon incident-antigen excess). The
sensitivity, specificity, positive predictive value and negative
predictive value of QFT-G for tuberculous pleurisy were
64.3%, 100%, 100% and 80.7%, respectively [3]. In the present
study, QFT-G test results were indeterminate in 13 patients
and positive in 10 patients in the tuberculous pleurisy group.
There was not a single patient whose test result was negative
in the tuberculous pleurisy group. It was determined that the
sensitivity, specificity, positive predictive value and negative
predictive value of QFT-G for tuberculous pleurisy was
43.5%, 54.5%, 30.3% and 100%, respectively.
In order for the QFT-G test to become useful in the diagno-
sis of tuberculous pleurisy, which test was designed to detect
latent TB infection, the result should be positive in the analy-
sis performed with serum in patients such as those with TB
infection, and in patients with pleural effusion such as non-
TB related malignancy. On the other hand, tests performed
with pleural fluid, the results should be negative. This finding
should give rise to thought that the lymphocytes sensitized
with TB remain in peripheral blood, yet are not present in
pleural fluid. However, this hypothesis has not yet been pro-
ven. Unless otherwise proven, whether or not such analyses
in the diagnosis of pleural effusion will make additional con-
tributions of more than just a free measurement of IFN-c in
pleural fluid will remain a controversial topic [25].
While the value of the QFT-GIT test in exclusion of tuber-
culous pleurisy was found to be higher in the present study,
its other diagnostic efficiency values were detected to be
low. Although the diagnostic sensitivities of both IGRAs were
higher than that of tuberculin skin tests, they were still not
high enough to use as a test to rule out TB. Also, positive evi-
dence for the use of IGRAs in compartments other than blood
will require more independent and carefully designed pro-
spective studies.
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